About C2i Genomics
C2i Genomics is a company based in New York (United States) founded in 2019 was acquired by Veracyte in January 2024. C2i Genomics has raised $112 million across 2 funding rounds from investors including ARE, Veracyte and Driehaus. C2i Genomics has completed 1 acquisition, including QnA DX. C2i Genomics offers products and services including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay. C2i Genomics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Veracyte, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of C2i Genomics
C2i Genomics offers a comprehensive portfolio of products and services, including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay.
Test for thyroid cancer detection using genomic sequencing.
Assay for prostate cancer risk assessment via genomics.
Tool for breast cancer prognosis using gene expression.
Test for bladder cancer monitoring with AI integration.
Platform for detecting residual cancer via whole-genome sequencing.
People of C2i Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of C2i Genomics
C2i Genomics has successfully raised a total of $112M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in C2i Genomics
C2i Genomics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Veracyte and Driehaus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Venture capital firm offering funding and tools for startups in technology and investment sectors.
|
Locked | Locked | Locked | |
|
Tech and life Science focused early stage VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for C2i Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by C2i Genomics
C2i Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include QnA DX.
Investment portfolio details for C2i Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone clinical diagnostic laboratory services are operated in Cambridge.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for C2i Genomics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - C2i Genomics
Detailed financials for C2i Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
C2i Genomics Comparisons
Peer comparison for C2i Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of C2i Genomics
C2i Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of C2i Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on C2i Genomics
Complete news archive for C2i Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about C2i Genomics
C2i Genomics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
C2i Genomics is headquartered in New York, United States. It is registered at New York, New York, United States.
C2i Genomics is a funded company, having raised a total of $112M across 2 funding rounds to date.
C2i Genomics was founded in 2019 and is based in New York, United States. Operations focus on the biotechnology sector, where liquid biopsy services are delivered for monitoring patients after cancer surgery. Genetic changes across tumors are detected through a specialized tool. Thousands of data points from routine blood tests are compared to tumor tissue sequences and whole-genome data using bioinformatics and AI methods.
C2i Genomics's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
C2i Genomics offers Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay.
C2i Genomics has made 1 acquisition, including QnA DX.
C2i Genomics has 11 investors. Key investors include ARE, Veracyte, Driehaus, Gordon Asset Management, and Casdin Capital.